- Home
- RGLS vs ASMB Comparison
RGLS vs ASMB Comparison
Compare RGLS & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGLS
- ASMB
- Stock Information
- Founded
- RGLS 2007
- ASMB 2005
- Country
- RGLS United States
- ASMB United States
- Employees
- RGLS N/A
- ASMB N/A
- Industry
- RGLS Biotechnology: Pharmaceutical Preparations
- ASMB Biotechnology: Pharmaceutical Preparations
- Sector
- RGLS Health Care
- ASMB Health Care
- Exchange
- RGLS Nasdaq
- ASMB Nasdaq
- Market Cap
- RGLS 106.7M
- ASMB 110.8M
- IPO Year
- RGLS 2012
- ASMB 2010
- Fundamental
- Price
- RGLS $1.48
- ASMB $16.79
- Analyst Decision
- RGLS Strong Buy
- ASMB Buy
- Analyst Count
- RGLS 6
- ASMB 2
- Target Price
- RGLS $10.33
- ASMB $35.00
- AVG Volume (30 Days)
- RGLS 263.0K
- ASMB 28.7K
- Earning Date
- RGLS 11-07-2024
- ASMB 11-06-2024
- Dividend Yield
- RGLS N/A
- ASMB N/A
- EPS Growth
- RGLS N/A
- ASMB N/A
- EPS
- RGLS N/A
- ASMB N/A
- Revenue
- RGLS N/A
- ASMB $21,481,000.00
- Revenue This Year
- RGLS N/A
- ASMB $267.67
- Revenue Next Year
- RGLS N/A
- ASMB $46.15
- P/E Ratio
- RGLS N/A
- ASMB N/A
- Revenue Growth
- RGLS N/A
- ASMB N/A
- 52 Week Low
- RGLS $1.08
- ASMB $7.68
- 52 Week High
- RGLS $3.79
- ASMB $19.93
- Technical
- Relative Strength Index (RSI)
- RGLS 44.54
- ASMB 51.49
- Support Level
- RGLS $1.47
- ASMB $17.27
- Resistance Level
- RGLS $1.65
- ASMB $18.98
- Average True Range (ATR)
- RGLS 0.11
- ASMB 1.23
- MACD
- RGLS -0.00
- ASMB 0.12
- Stochastic Oscillator
- RGLS 15.79
- ASMB 55.03
About RGLS Regulus Therapeutics Inc.
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.